Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics) - Hardcover

Hardcover

ISBN 10: 1482231697 ISBN 13: 9781482231694

Verlag: Chapman & Hall/CRC, 2017

Inhaltsangabe

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

Über diesen Titel

Über die Autorin bzw. den Autor

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer , Dr. Ralph D’Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.

Details zur Ausgabe

• Verlag: Chapman & Hall/CRC
• Erscheinungsdatum: 2017
• Sprache: Englisch
• ISBN 10: 1482231697
• ISBN 13: 9781482231694
• Einband: Gebundene Ausgabe
• Auflage: 1
• Anzahl der Seiten: 248
• Herausgeber: Barker Kerry B., Menon Sandeep M., D'Agostino Ralph B. Sr., Xu Siyan, Jin Bo
• Kontakt zum Hersteller: Nicht verfügbar
• Verantwortliche Person: Logos Europe; contact@logoseurope.eu; ; rue Nicolas Poussin 9; La Rochelle; 17000; Frankreich